Revolutionizing Cell Particle Analysis: How Barcode Labeling Enhances Scientific Research
Small extracellular vesicles (sEVs) play an important role in how cells communicate. The “cargo” they carry, which includes RNA, proteins, and lipids, affects tissue health and disease spread. Researchers want to understand how sEVs form and are released, but current methods to study them are slow and complex.
A team in Japan has created a new tool called CIBER (CRISPR-assisted individually barcoded sEV-based release regulator). This system allows researchers to screen for sEV release regulators quickly, compared to older methods. Associate Professor Ryosuke Kojima from the University of Tokyo explains that CIBER can conduct a genome-wide screening in a few weeks to months.
CIBER employs CRISPR-guide RNA to disable specific genes in cells, and then barcodes are added to the sEVs released by these cells. This lets scientists track how many sEVs each cell releases. Traditional methods require scientists to isolate cells and vary gene activity in each one, making the process lengthy. CIBER, however, can study many cells with different gene knockouts at once, making it easier to understand the release of sEVs.
What are the implications of small extracellular vesicles (sEVs) in cancer research and therapy?
Interview with Associate Professor Ryosuke Kojima on CIBER and the Future of Small Extracellular Vesicle Research
NewsDirectory3.com: Thank you for joining us, Associate Professor Kojima. Can you explain the role of small extracellular vesicles (sEVs) in cellular communication and why they are critical for understanding tissue health and disease?
Ryosuke Kojima: Thank you for having me. Small extracellular vesicles are crucial for intercellular communication. They carry a variety of biological cargo, including RNA, proteins, and lipids, influencing how cells interact with each other. This communication is especially important in the context of diseases like cancer, where sEVs can contribute to both tumor progression and metastasis. By studying sEVs, we can gain significant insights into cellular functions and the mechanisms that drive disease.
NewsDirectory3.com: Current methods for studying sEVs are often slow and complex. How does CIBER improve this process?
Ryosuke Kojima: Traditional methods typically involve isolating individual cells and altering gene activity one at a time, which can be time-consuming and labor-intensive. CIBER, our new tool, allows for genome-wide screenings within a matter of weeks to months. It utilizes CRISPR technology to disable specific genes in multiple cells simultaneously. By barcoding the sEVs released from these cells, we can efficiently track and analyze the sEV release, which significantly accelerates our research efforts.
NewsDirectory3.com: Can you elaborate on the technical aspects of how CIBER functions?
Ryosuke Kojima: Certainly. CIBER employs CRISPR-guide RNA to target and disable genes associated with sEV release. Once these genes are knocked out, we add unique barcodes to the sEVs produced by these modified cells. This allows us to measure the quantity of sEVs per cell and makes it possible to study how different genes affect the dynamics of sEV release in a high-throughput manner.
NewsDirectory3.com: What potential applications do you foresee for CIBER in therapeutic settings, particularly concerning cancer?
Ryosuke Kojima: The most exciting possibility is the identification of new therapeutic targets. CIBER can help us discover genes that regulate sEV release, which could lead to novel treatments that enhance or inhibit this process. Additionally, increasing the production of sEVs may provide therapeutic benefits, such as delivering drugs or RNA-based therapies directly to target cells. This could revolutionize our approach to treating diseases like cancer.
NewsDirectory3.com: Beyond cancer, what other areas of research do you think will benefit from CIBER?
Ryosuke Kojima: CIBER’s capabilities extend beyond cancer research. It can be adapted to study other diseases where cell communication plays a vital role, such as neurodegenerative diseases or cardiovascular conditions. Moreover, the ability to track cell behavior through barcoded sEVs opens doors to understanding fundamental biological processes without disrupting the cells’ native functions.
NewsDirectory3.com: What is the next step for your research team following the development of CIBER?
Ryosuke Kojima: Our immediate next step is to validate CIBER across various cell types and conditions to ensure it works broadly in different biological contexts. We are also exploring partnerships with clinical researchers to evaluate how the insights gained from CIBER can be translated into real-world applications. We believe that with continued refinement and testing, CIBER has the potential to make significant contributions to both fundamental biology and clinical research in the future.
NewsDirectory3.com: Thank you, Associate Professor Kojima, for your insights into this exciting development in sEV research.
Ryosuke Kojima: Thank you for the opportunity to discuss our work!
Looking ahead, CIBER may help identify new treatments and boost the production of sEVs for therapeutic uses, like treating cancer. Additionally, barcoded sEVs can provide insights into cell behavior without harming the cells. The researchers believe CIBER has great potential for advancing sEV biology.